A leap towards effective and safe treatment for neuropathic pain: a strategic initiative for enhanced healthcare and societal well-being

AKIGAI’s initiative is set to transform the treatment of Neuropathic Pain (NeuP) by bringing a NeuP drug to market – an EGFR-Inhibitor (EGFR-I) which has been demonstrated by AKIGAI to effectively alleviate NeuP symptoms. NeuP, an intense and often chronic form of pain, affects almost 10% of the global population, being recognized as one of the most difficult pain-types to manage. The AKIGAI drug has demonstrated a success rate where at least 2 out of 3 patients experience significant pain reduction, a notable improvement over current treatments that only see a 1 in 8 success rate. Bringing the effective AKIGAI NeuP drug to market is a pivotal step in addressing the challenge of NeuP. However, this initiative encounters the strategic challenge of motivating Big Pharma to repurpose their premium EGFR-Is for NeuP treatment, considering the different financial implications compared to their existing markets. AKIGAI’s project will concentrate on market preparation, stakeholder engagement, team empowerment, and investor relations enhancement. This strategic approach includes upgrading the business model, strengthen IPR portfolio, updating and consolidating the business plan and growth strategy, as well as validating the business model. By aligning its business strategy with the clinical efficacy of EGFR-Is in relieving NeuP, AKIGAI is not only advancing in the healthcare sector but also strengthening its market position and contributing to the broader goals of healthcare innovation and societal well-being. This project is set to position AKIGAI as a frontrunner in NeuP treatment, underlining its commitment to healthcare innovation and the betterment of patient outcomes.